aqua/water/eau, butyrospermum parkii (shea) butter, prunus amygdalus dulcis (sweet almond) oil, glycerin, butylene glycol, caprylic/capric triglyceride, dimethicone, cetyl alcohol, helianthus annuus (sunflower) seed oil, cetearyl alcohol, hydrolyzed jojoba esters, myristyl myristate, isostearyl isostearate, argania spinosa kernel oil, vitis vinifera (grape) seed extract, sodium hyaluronate, magnolia officinalis bark extract, citrus aurantium amara (bitter orange) peel extract, angelica archangelica root extract, pongamia pinnata seed extract, coffea arabica (coffee) seed extract, camellia sinensis leaf extract, ascorbyl palmitate, bisabolol, jojoba esters, bifida ferment lysate, tocopheryl acetate, linum usitatissimum (linseed) seed oil, cichorium intybus (chicory) root extract, tocopherol, pisum sativum (pea) extract, linoleic acid, linolenic acid, cynara scolymus (artichoke) leaf extract, acetyl dipeptide-1 cetyl ester, borago officinalis seed oil, glycyrrhiza uralensis (licorice) root extract, glycyrrhiza glabra (licorice) rhizome/root extract, glycyrrhiza glabra (licorice) root extract, oleic acid, hdi/trimethylol hexyllactone crosspolymer, cetyl stearate, stearic acid, cetearyl glucoside, potassium cetyl phosphate, xanthan gum, methyl methacrylate crosspolymer, chlorphenesin, carbomer, parfum/fragrance, ethylhexyl palmitate, disodium edta, maltodextrin, palmitic acid, lecithin, citric acid, peg-8, silica, laureth-3, hydroxyethylcellulose, linalool, benzyl benzoate, alcohol, sodium citrate, citronellol, benzyl salicylate, butylphenyl methylpropional, silica dimethyl silylate, ethylhexylglycerin, hydroxycitronellal, sodium benzoate, hexyl cinnamal, limonene, acetic acid, caprylyl glycol, magnesium aluminum silicate, lactic acid, ascorbic acid, farnesol, sclerotium gum, hexylene glycol, phenoxyethanol, sorbic acid, bht
Helps increase thermogenesis and sweat response
The cost of Wegovy can be high, and patients need to check their insurance plans for coverage
Typical Oncology Drug FDA Approved in 2025: Datroway (Datopotamab Deruxtecan dlnk, ADC, Trop 2) Indication: For the treatment of unresectable or metastatic, hormone receptor-positive, HER2-negative breast cancer in patients previously treated with endocrine therapy and chemotherapy for metastatic disease
